Grants

Defense Health Agency Contracting Activity - DHACA

Summary: The fiscal year 2026 Toxic Exposures Research Program (TERP) Investigator-Initiated Research Award (IIRA) is intended to support studies that will make an important contribution toward research and/or patient care for diseases or conditions associated with military-related toxic exposures. Research projects may focus on any phase of research from basic laboratory research through translational research, including preclinical studies in animal models and human subjects, as well as correlative studies associated with an existing clinical trial. New Approach Methodologies may also be used. https://cdmrp.health.mil/pubs/press/2026/terppreann

Free to search & build · $99 one-time to unlock the application pack · No subscription

DoW Toxic Exposures Investigator Initiated Research Award

Dept. of the Army -- USAMRAA

Summary: The fiscal year 2026 Toxic Exposures Research Program (TERP) Investigator-Initiated Research Award (IIRA) is intended to support studies that will make an important contribution toward research and/or patient care for diseases or conditions associated with military-related toxic exposures. Research projects may focus on any phase of research from basic laboratory research through translational research, including preclinical studies in animal models and human subjects, as well as correlative studies associated with an existing clinical trial. New Approach Methodologies may also be used. <a href="https://cdmrp.health.mil/pubs/press/2026/terppreann" target="_blank">https://cdmrp.health.mil/pubs/press/2026/terppreann</a>

science_technology_and_other_research_and_development

Free to search & build · $99 one-time to unlock the application pack · No subscription

DoW Toxic Exposures Translational Research Award

Dept. of the Army -- USAMRAA

DoW Toxic Exposures Translational Research Award

research

Free to search & build · $99 one-time to unlock the application pack · No subscription

DoW Toxic Exposures Translational Research Award

Defense Health Agency Contracting Activity - DHACA

Summary: The intent of the fiscal year 2026 (FY26) Toxic Exposures Research Program (TERP) Translational Research Award (TRA) is to support translational research that will accelerate the movement of promising ideas in military-related toxic exposure research into clinical applications, including health care products, interventions, technologies and/or clinical practice guidelines. Translational research may be defined as an integration of basic science and clinical observations. New Approach Methodologies may also be used. Applications should provide evidence for the reciprocal transfer of information between basic and clinical science, or vice versa, in developing and implementing the research plan. Distinctive Features: To encourage applications that include meaningful and productive collaborations, the FY26 TERP TRA includes a Partnering Principal Investigator Option (PPIO). One Principal Investigator (PI) is identified as the initiating PI, and an additional PI may be identified as a Partnering PI. If recommended for funding, each PI will be named on separate awards. The intent is to support interdisciplinary partnerships, such as those between clinicians and research scientists, that will accelerate the movement of promising ideas into clinical applications. Partnering should significantly advance the research beyond what would be possible through individual efforts. https://cdmrp.health.mil/pubs/press/2026/terppreann

Free to search & build · $99 one-time to unlock the application pack · No subscription

DoW Toxic Exposures Translational Research Award

Defense Health Agency Contracting Activity - DHACA

Summary: The intent of the fiscal year 2026 (FY26) Toxic Exposures Research Program (TERP) Translational Research Award (TRA) is to support translational research that will accelerate the movement of promising ideas in military-related toxic exposure research into clinical applications, including health care products, interventions, technologies and/or clinical practice guidelines. Translational research may be defined as an integration of basic science and clinical observations. New Approach Methodologies may also be used. Applications should provide evidence for the reciprocal transfer of information between basic and clinical science, or vice versa, in developing and implementing the research plan.  Distinctive Features: To encourage applications that include meaningful and productive collaborations, the FY26 TERP TRA includes a Partnering Principal Investigator Option (PPIO). One Principal Investigator (PI) is identified as the initiating PI, and an additional PI may be identified as a Partnering PI. If recommended for funding, each PI will be named on separate awards. The intent is to support interdisciplinary partnerships, such as those between clinicians and research scientists, that will accelerate the movement of promising ideas into clinical applications. Partnering should significantly advance the research beyond what would be possible through individual efforts. <a href="https://cdmrp.health.mil/pubs/press/2026/terppreann" target="_blank">https://cdmrp.health.mil/pubs/press/2026/terppreann</a>

science_technology_and_other_research_and_development

Free to search & build · $99 one-time to unlock the application pack · No subscription

DoW Traumatic Brain Injury and Psychological Health, Clinical Trial Award

Defense Health Agency Contracting Activity - DHACA

Summary: The fiscal year 2026 (FY26) Traumatic Brain Injury and Psychological Health Research Program (TBIPHRP) Clinical Trial Award (CTA) intends to support clinical trials with the potential to have a significant impact on psychological health conditions and/or traumatic brain injury (TBI) through clinical applications, including health care products, technologies and/or practice guidelines. Distinctive Features: Funding from this award mechanism must support a clinical trial. Clinical trials may be designed to evaluate a wide range of interventions, including new drugs, biologics, medical devices, diagnostics, therapies and behavioral health strategies. Preliminary data are required. The inclusion of community-based participatory research (CBPR) approaches is required. The CTA offers funding for two Research Levels. The applicant is responsible for selecting the Research Level based on the scope of the research. Research Level 1: Supports proof-of-principle pilot studies, as well as phase 1 and phase 2 clinical trials. Research Level 2: Supports larger-scale and advanced clinical trials that evaluate effectiveness in relevant patient populations. Early-Career Investigator Partnering Option (available for both Research Levels): This option accommodates two Principal Investigators (PIs), one of which is an Early-Career Investigator. If recommended for funding, each PI will receive a separate award.

Free to search & build · $99 one-time to unlock the application pack · No subscription

DoW Traumatic Brain Injury and Psychological Health, Clinical Trial Award

Defense Health Agency Contracting Activity - DHACA

Summary: The fiscal year 2026 (FY26) Traumatic Brain Injury and Psychological Health Research Program (TBIPHRP) Clinical Trial Award (CTA) intends to support clinical trials with the potential to have a significant impact on psychological health conditions and/or traumatic brain injury (TBI) through clinical applications, including health care products, technologies and/or practice guidelines.  Distinctive Features: Funding from this award mechanism must support a clinical trial.·        Clinical trials may be designed to evaluate a wide range of interventions, including new drugs, biologics, medical devices, diagnostics, therapies and behavioral health strategies.·        Preliminary data are required.·        The inclusion of community-based participatory research (CBPR) approaches is required.·        The CTA offers funding for two Research Levels. The applicant is responsible for selecting the Research Level based on the scope of the research.○       Research Level 1: Supports proof-of-principle pilot studies, as well as phase 1 and phase 2 clinical trials.○       Research Level 2: Supports larger-scale and advanced clinical trials that evaluate effectiveness in relevant patient populations.·        Early-Career Investigator Partnering Option (available for both Research Levels): This option accommodates two Principal Investigators (PIs), one of which is an Early-Career Investigator. If recommended for funding, each PI will receive a separate award.

science_technology_and_other_research_and_development

Free to search & build · $99 one-time to unlock the application pack · No subscription

DoW Traumatic Brain Injury and Psychological Health, Health Services Research Award

Defense Health Agency Contracting Activity - DHACA

Summary: The fiscal year 2026 (FY26) Traumatic Brain Injury and Psychological Health Research Program (TBIPHRP) Health Services Research Award (HSRA) intends to fund high-impact research that bridges the gap between research, practice and policy by building real-world evidence on how interventions, clinical practices/guidelines, or policies can be deployed to targeted populations at the appropriate time. In order to meet this intent, the mechanism supports health services research approaches. Distinctive Features: ·        The HSRA will support health services research approaches that include comparative effectiveness research; implementation of interventions, diagnostics and clinical practices/guidelines; and validation of data science insights. ·        Applications must include <a href="https://ebrap.org/eBRAP/public/gai.htm?version=CD26_01#_Definition_List:~:text=considered%20clinical%20trials.-,Clinical%20Research%3A,-For%20the%20purposes" target="_blank">clinical research</a> or <a href="https://ebrap.org/eBRAP/public/gai.htm?version=CD26_01#_Definition_List:~:text=or%20hardware%20procurement.-,Clinical%20Trial%3A,-As%20defined%20in" target="_blank">clinical trials</a>. Prospective or retrospective clinical research or clinical trials involving human subjects, human subject data/records, and human anatomical substances are allowed. ·        Preliminary data are required. ·        Basic, preclinical and animal research are prohibited. ·        For research prospectively enrolling human subjects, inclusion of community-based participatory research (CBPR) approaches is required. ·        Early-Career Investigator Partnering Option: This option accommodates two Principal Investigators (PIs), one of which is an Early-Career Investigator. If recommended for funding, each PI will receive a separate award.

science_technology_and_other_research_and_development

Free to search & build · $99 one-time to unlock the application pack · No subscription

DoW Traumatic Brain Injury and Psychological Health, Health Services Research Award

Defense Health Agency Contracting Activity - DHACA

Summary: The fiscal year 2026 (FY26) Traumatic Brain Injury and Psychological Health Research Program (TBIPHRP) Health Services Research Award (HSRA) intends to fund high-impact research that bridges the gap between research, practice and policy by building real-world evidence on how interventions, clinical practices/guidelines, or policies can be deployed to targeted populations at the appropriate time. In order to meet this intent, the mechanism supports health services research approaches. Distinctive Features: The HSRA will support health services research approaches that include comparative effectiveness research; implementation of interventions, diagnostics and clinical practices/guidelines; and validation of data science insights. Applications must include clinical research or clinical trials. Prospective or retrospective clinical research or clinical trials involving human subjects, human subject data/records, and human anatomical substances are allowed. Preliminary data are required. Basic, preclinical and animal research are prohibited. For research prospectively enrolling human subjects, inclusion of community-based participatory research (CBPR) approaches is required. Early-Career Investigator Partnering Option: This option accommodates two Principal Investigators (PIs), one of which is an Early-Career Investigator. If recommended for funding, each PI will receive a separate award.

Free to search & build · $99 one-time to unlock the application pack · No subscription

DoW Traumatic Brain Injury and Psychological Health, Translational Research Award

Defense Health Agency Contracting Activity - DHACA

Summary: The Translational Research Award (TRA) intends to accelerate the conversion of scientific findings into impactful clinical applications. The TRA prioritizes innovative approaches over purely iterative or incremental research. Submissions focusing on minor modifications to existing standards without the intent or potential to significantly improve clinical care or patient outcomes do not meet the intent of the mechanism.Distinctive Features: Basic research and clinical trials are prohibited. Preliminary data are required. For animal research, applications must describe the choice of model and its relevance to the human clinical condition. For research prospectively enrolling human subjects, the inclusion of community-based participatory research (CBPR) approaches is required. The Translational Research Award offers funding for two Research Levels. The applicant is responsible for selecting the Research Level based on the scope of the research. Research Level 1: Supports the refinement of mature ideas and concepts into tangible and knowledge products positioned for further evaluation. Research Level 2: Supports the rigorous evaluation of tangible and knowledge products in preparation for first-in-human studies or clinical trials. Early-Career Investigator Partnering Option (available for both Research Levels): This option accommodates two Principal Investigators (PIs), one of which is an Early-Career Investigator. If recommended for funding, each PI will receive a separate award.

Free to search & build · $99 one-time to unlock the application pack · No subscription

DoW Traumatic Brain Injury and Psychological Health, Translational Research Award

Dept. of the Army -- USAMRAA

Summary: The Translational Research Award (TRA) intends to accelerate the conversion of scientific findings into impactful clinical applications. The TRA prioritizes innovative approaches over purely iterative or incremental research. Submissions focusing on minor modifications to existing standards without the intent or potential to significantly improve clinical care or patient outcomes do not meet the intent of the mechanism.Distinctive Features: Basic research and clinical trials are prohibited. Preliminary data are required.·        For animal research, applications must describe the choice of model and its relevance to the human clinical condition.·        For research prospectively enrolling human subjects, the inclusion of community-based participatory research (CBPR) approaches is required.·        The Translational Research Award offers funding for two Research Levels. The applicant is responsible for selecting the Research Level based on the scope of the research.○       Research Level 1: Supports the refinement of mature ideas and concepts into tangible and knowledge products positioned for further evaluation.○       Research Level 2: Supports the rigorous evaluation of tangible and knowledge products in preparation for first-in-human studies or clinical trials.·        Early-Career Investigator Partnering Option (available for both Research Levels): This option accommodates two Principal Investigators (PIs), one of which is an Early-Career Investigator. If recommended for funding, each PI will receive a separate award.

science_technology_and_other_research_and_development

Free to search & build · $99 one-time to unlock the application pack · No subscription

DoW Tuberous Sclerosis Complex, Clinical Translational Research Award

Defense Health Agency Contracting Activity - DHACA

Summary: The fiscal year 2026 (FY26) Tuberous Sclerosis Complex Research Program (TSCRP) Clinical Translational Research Award (CTRA) supports studies that will move promising, well-founded preclinical and/or clinical research findings closer to clinical application, including diagnosis, prognosis or treatment of tuberous sclerosis complex (TSC).Distinctive Features: This funding mechanism allows for multiple Principal Investigators (PIs). Only the initiating PI will submit a pre-application, but all PIs will need to submit full applications. The partnering PI(s) application is an abbreviated package specific to their distinct portion of the research project. Be advised, all associated applications for a research project may be withdrawn if the initiating or partnering application is rejected or administratively withdrawn.

Free to search & build · $99 one-time to unlock the application pack · No subscription

DoW Tuberous Sclerosis Complex, Clinical Translational Research Award

Defense Health Agency Contracting Activity - DHACA

Summary: The fiscal year 2026 (FY26) Tuberous Sclerosis Complex Research Program (TSCRP) Clinical Translational Research Award (CTRA) supports studies that will move promising, well-founded preclinical and/or clinical research findings closer to clinical application, including diagnosis, prognosis or treatment of tuberous sclerosis complex (TSC). Distinctive Features: This funding mechanism allows for multiple Principal Investigators (PIs). Only the initiating PI will submit a pre-application, but all PIs will need to submit full applications. The partnering PI(s) application is an abbreviated package specific to their distinct portion of the research project. Be advised, all associated applications for a research project may be withdrawn if the initiating or partnering application is rejected or administratively withdrawn.

science_technology_and_other_research_and_development

Free to search & build · $99 one-time to unlock the application pack · No subscription

DoW Tuberous Sclerosis Complex, Exploration-Hypothesis Development Award

Defense Health Agency Contracting Activity - DHACA

Summary: The fiscal year 2026 (FY26) Tuberous Sclerosis Complex Research Program (TSCRP) Exploration-Hypothesis Development Award (EHDA) supports the initial exploration of innovative, high-risk, high-gain and potentially groundbreaking concepts in the tuberous sclerosis complex (TSC) research field. Distinctive Features: Preliminary Data is not required. Applications should demonstrate the ability to achieve interpretable results in the absence of preliminary data supporting the hypothesis.

science_technology_and_other_research_and_development

Free to search & build · $99 one-time to unlock the application pack · No subscription

DoW Tuberous Sclerosis Complex, Exploration-Hypothesis Development Award

Defense Health Agency Contracting Activity - DHACA

Summary: The fiscal year 2026 (FY26) Tuberous Sclerosis Complex Research Program (TSCRP) Exploration-Hypothesis Development Award (EHDA) supports the initial exploration of innovative, high-risk, high-gain and potentially groundbreaking concepts in the tuberous sclerosis complex (TSC) research field.Distinctive Features: Preliminary Data is not required. Applications should demonstrate the ability to achieve interpretable results in the absence of preliminary data supporting the hypothesis.

Free to search & build · $99 one-time to unlock the application pack · No subscription

DoW Tuberous Sclerosis Complex, Idea Development Award

Defense Health Agency Contracting Activity - DHACA

Summary: The fiscal year 2026 (FY26) Tuberous Sclerosis Complex Research Program (TSCRP) Idea Development Award (IDA) supports conceptually innovative and high-impact research that could ultimately lead to critical discoveries in tuberous sclerosis complex (TSC) research and/or improvements in patient care.Distinctive Features: This funding mechanism allows for established and new-to-the-field investigators. New-to-the-field investigators are independent investigators that are early in their faculty appointments and/or established investigators transitioned from other research fields into TSC research. Applications to the New-to-the-Field option will compete separately from the Established Investigators submitting to the regular Idea Development Award (IDA).

Free to search & build · $99 one-time to unlock the application pack · No subscription

DoW Tuberous Sclerosis Complex, Idea Development Award

Dept. of the Army -- USAMRAA

DoW Tuberous Sclerosis Complex, Idea Development Award

general

Free to search & build · $99 one-time to unlock the application pack · No subscription

DoW Tuberous Sclerosis Complex, Idea Development Award

Defense Health Agency Contracting Activity - DHACA

Summary: The fiscal year 2026 (FY26) Tuberous Sclerosis Complex Research Program (TSCRP) Idea Development Award (IDA) supports conceptually innovative and high-impact research that could ultimately lead to critical discoveries in tuberous sclerosis complex (TSC) research and/or improvements in patient care. Distinctive Features: This funding mechanism allows for established and new-to-the-field investigators. New-to-the-field investigators are independent investigators that are early in their faculty appointments and/or established investigators transitioned from other research fields into TSC research. Applications to the New-to-the-Field option will compete separately from the Established Investigators submitting to the regular Idea Development Award (IDA).

science_technology_and_other_research_and_development

Free to search & build · $99 one-time to unlock the application pack · No subscription

DoW Vision, Clinical Trial Award

Defense Health Agency Contracting Activity - DHACA

Summary: The fiscal year 2026 (FY26) Vision Research Program (VRP) Clinical Trial Award (CTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of service-connected eye injury and visual dysfunction. Research must align with at least one of the FY26 VRP Focus Areas. Distinctive Features: For interventions that require Investigational New Drug (IND)/Investigational Device Exemption (IDE) or equivalent regulatory authorizations for clinical testing, the IND/IDE application or equivalent must be submitted to the relevant Regulatory Agency by the CTA application submission deadline. In addition, applicants must provide documentation of communication from the Regulatory Agency indicating that the IND/IDE or equivalent is active/safe to proceed by March 1, 2027, in order for the CTA application to be considered for funding. Refer to Attachment 7: Regulatory Strategy for further details. Scored peer review criteria include Clinical Impact; Research Strategy and Feasibility; Recruitment, Accrual, Retention; Regulatory Strategy and Transition Plan; Statistical Plan and Data Analysis; Ethical Considerations; Personnel and Communication. Programmatic review criteria include adherence to the intent of the CTA, contribution to program portfolio, relative impact and relevance to military health. https://cdmrp.health.mil/pubs/press/2026/vrppreann

Free to search & build · $99 one-time to unlock the application pack · No subscription

DoW Vision, Clinical Trial Award

Defense Health Agency Contracting Activity - DHACA

Summary: The fiscal year 2026 (FY26) Vision Research Program (VRP) Clinical Trial Award (CTA) supports the rapid implementation of <a href="https://ebrap.org/eBRAP/public/gai.htm?version=CD26_01#_Definition_List:~:text=or%20hardware%20procurement.-,Clinical%20Trial%3A,-As%20defined%20in" target="_blank">clinical trials</a> with the potential to have a significant impact on the treatment or management of service-connected eye injury and visual dysfunction. Research must align with at least one of the <a href="https://militaryhealth-my.sharepoint-mil.us/personal/teresa_m_parkerreeser_civ_health_mil/Documents/Documents/FY%202026/VRP/HT942526VRPCTA_GG.docx#Focus_Area" target="_blank">FY26 VRP Focus Areas</a>.   Distinctive Features: ·       For interventions that require Investigational New Drug (IND)/Investigational Device Exemption (IDE) or equivalent regulatory authorizations for clinical testing, the IND/IDE application or equivalent must be submitted to the relevant <a href="https://militaryhealth-my.sharepoint-mil.us/personal/teresa_m_parkerreeser_civ_health_mil/Documents/Documents/FY%202026/VRP/HT942526VRPCTA_GG.docx#RegulatoryAgency" target="_blank">Regulatory Agency</a> by the CTA application submission deadline. In addition, applicants must provide documentation of communication from the Regulatory Agency indicating that the IND/IDE or equivalent is active/safe to proceed by March 1, 2027, in order for the CTA application to be considered for funding. Refer to <a href="https://militaryhealth-my.sharepoint-mil.us/personal/teresa_m_parkerreeser_civ_health_mil/Documents/Documents/FY%202026/VRP/HT942526VRPCTA_GG.docx#Attach9_RegStrategy" target="_blank">Attachment 7: Regulatory Strategy</a> for further details. ·       Scored <a href="https://militaryhealth-my.sharepoint-mil.us/personal/teresa_m_parkerreeser_civ_health_mil/Documents/Documents/FY%202026/VRP/HT942526VRPCTA_GG.docx#Peer_Review" target="_blank">peer review criteria</a> include Clinical Impact; Research Strategy and Feasibility; Recruitment, Accrual, Retention; Regulatory Strategy and Transition Plan; Statistical Plan and Data Analysis; Ethical Considerations; Personnel and Communication. ·       <a href="https://militaryhealth-my.sharepoint-mil.us/personal/teresa_m_parkerreeser_civ_health_mil/Documents/Documents/FY%202026/VRP/HT942526VRPCTA_GG.docx#Programmatic_Review" target="_blank">Programmatic review criteria</a> include adherence to the intent of the CTA, contribution to program portfolio, relative impact and relevance to military health. <a href="https://cdmrp.health.mil/pubs/press/2026/vrppreann " target="_blank">https://cdmrp.health.mil/pubs/press/2026/vrppreann </a>

science_technology_and_other_research_and_development

Free to search & build · $99 one-time to unlock the application pack · No subscription

DoW Vision, Investigator-Initiated Research Award

Defense Health Agency Contracting Activity - DHACA

Summary: The fiscal year 2026 (FY26) Vision Research Program (VRP) Investigator-Initiated Research Award (IIRA) supports basic through early translational research that will yield highly impactful discoveries or major advancements in the research and/or patient care of eye injury and/or visual dysfunction related to military exposure. The IIRA may be used to support preclinical studies and/or clinical research. Research must align with at least one of the FY26 VRP Focus Areas. The IIRA cannot be used to support clinical trials. Distinctive Features: The IIRA offers two Funding Levels to support research at different stages and the exploration/development of ideas of different maturity levels. Funding Level 2 includes a Partnering Principal Investigator (PI) Option (PPIO) for two PIs, an Initiating PI and a Partnering PI. Scored peer review criteria include Research Idea/Rationale, Research Strategy and Feasibility, Impact, and Personnel. Programmatic review criteria include adherence to the intent of the IIRA, contribution to the VRP portfolio, relative impact, and relevance to military health. The VRP may share FY26 IIRA applications and reviews with the National Eye Institute (NEI) for independent funding consideration. https://cdmrp.health.mil/pubs/press/2026/vrppreann

Free to search & build · $99 one-time to unlock the application pack · No subscription

DoW Vision, Investigator-Initiated Research Award

Defense Health Agency Contracting Activity - DHACA

Summary: The fiscal year 2026 (FY26) Vision Research Program (VRP) Investigator-Initiated Research Award (IIRA) supports basic through early translational research that will yield highly impactful discoveries or major advancements in the research and/or patient care of eye injury and/or visual dysfunction related to military exposure. The IIRA may be used to support preclinical studies and/or <a href="https://ebrap.org/eBRAP/public/gai.htm?version=CD26_01#_Definition_List:~:text=considered%20clinical%20trials.-,Clinical%20Research,-%3A%20For%20the" target="_blank">clinical research</a>. Research must align with at least one of the <a href="https://militaryhealth-my.sharepoint-mil.us/personal/teresa_m_parkerreeser_civ_health_mil/Documents/Documents/FY%202026/VRP/HT942526VRPIIRA_GG.docx#Focus_Areas" target="_blank">FY26 VRP Focus Areas</a>. The IIRA cannot be used to support <a href="https://ebrap.org/eBRAP/public/gai.htm?version=CD26_01#_Definition_List:~:text=or%20hardware%20procurement.-,Clinical%20Trial%3A,-As%20defined%20in" target="_blank">clinical trials</a>. Distinctive Features: ·        The IIRA offers two <a href="https://militaryhealth-my.sharepoint-mil.us/personal/teresa_m_parkerreeser_civ_health_mil/Documents/Documents/FY%202026/VRP/HT942526VRPIIRA_GG.docx#FundingLevels" target="_blank">Funding Levels</a> to support research at different stages and the exploration/development of ideas of different maturity levels. ·        Funding Level 2 includes a <a href="https://militaryhealth-my.sharepoint-mil.us/personal/teresa_m_parkerreeser_civ_health_mil/Documents/Documents/FY%202026/VRP/HT942526VRPIIRA_GG.docx#PPIO" target="_blank">Partnering Principal Investigator (PI) Option (PPIO)</a> for two PIs, an Initiating PI and a Partnering PI. ·        Scored <a href="https://militaryhealth-my.sharepoint-mil.us/personal/teresa_m_parkerreeser_civ_health_mil/Documents/Documents/FY%202026/VRP/HT942526VRPIIRA_GG.docx#Peer_Review" target="_blank">peer review criteria</a> include Research Idea/Rationale, Research Strategy and Feasibility, Impact, and Personnel. ·        <a href="https://militaryhealth-my.sharepoint-mil.us/personal/teresa_m_parkerreeser_civ_health_mil/Documents/Documents/FY%202026/VRP/HT942526VRPIIRA_GG.docx#Programmatic_Review" target="_blank">Programmatic review criteria</a> include adherence to the intent of the IIRA, contribution to the VRP portfolio, relative impact, and relevance to military health. ·        The VRP may share FY26 IIRA applications and reviews with the National Eye Institute (NEI) for independent funding consideration. <a href="https://cdmrp.health.mil/pubs/press/2026/vrppreann" target="_blank">https://cdmrp.health.mil/pubs/press/2026/vrppreann</a>

science_technology_and_other_research_and_development

Free to search & build · $99 one-time to unlock the application pack · No subscription

DoW Vision, Mentored Clinical Research Award

science_technology_and_other_research_and_development

Defense Health Agency Contracting Activity - DHACA

Summary: The fiscal year 2026 (FY26) Vision Research Program (VRP) Mentored Clinical Research Award (MCRA) supports patient-oriented vision injury research conducted by highly motivated military or civilian clinicians in training. The MCRA may be used to support a standalone study of high impact to vision injury care or the generation of clinical research data in preparation for a more expansive study. Research must align with at least one of the <a href="https://militaryhealth-my.sharepoint-mil.us/personal/teresa_m_parkerreeser_civ_health_mil/Documents/Documents/FY%202026/VRP/HT942526VRPMCRA_GG.docx#FocusAreas" target="_blank">FY26 VRP Focus Areas</a>. The MCRA may not be used to support preclinical research or <a href="https://ebrap.org/eBRAP/public/gai.htm?version=CD26_01#_Definition_List:~:text=or%20hardware%20procurement.-,Clinical%20Trial%3A,-As%20defined%20in" target="_blank">clinical trials</a>. Distinctive Features: ·        Key personnel must include an established clinician or Ph.D. clinical scientist, who will serve as Principal Investigator (PI) and a clinician in training (e.g., a fellow, resident, junior clinician, clinician in a Ph.D. program), who will conduct the proposed research under mentorship of the PI, with support from supporting personnel as appropriate. ·        The clinician in training should have sufficient time remaining in their training program to complete the research proposed under the MCRA.  ·        Scored <a href="https://militaryhealth-my.sharepoint-mil.us/personal/teresa_m_parkerreeser_civ_health_mil/Documents/Documents/FY%202026/VRP/HT942526VRPMCRA_GG.docx#PeerReviewCriteria622" target="_blank">peer review criteria</a> include Research Idea/Rationale, Research Strategy and Feasibility, Impact and Personnel. ·        <a href="https://militaryhealth-my.sharepoint-mil.us/personal/teresa_m_parkerreeser_civ_health_mil/Documents/Documents/FY%202026/VRP/HT942526VRPMCRA_GG.docx#Programmatic_Review" target="_blank">Programmatic review criteria</a> include adherence to the intent of the MCRA, contribution to program portfolio, relative impact and relevance to military health. ·        Applicants must submit documentation of Institutional Review Board (IRB)/Ethics Committee (EC) approval or exemption by January 1, 2027, in order for the MCRA application to be considered for funding.  <a href="https://cdmrp.health.mil/pubs/press/2026/vrppreann" target="_blank">https://cdmrp.health.mil/pubs/press/2026/vrppreann</a>

2026-09-10

Free to search & build · $99 one-time to unlock the application pack · No subscription

DoW Vision, Mentored Clinical Research Award

Defense Health Agency Contracting Activity - DHACA

Summary: The fiscal year 2026 (FY26) Vision Research Program (VRP) Mentored Clinical Research Award (MCRA) supports patient-oriented vision injury research conducted by highly motivated military or civilian clinicians in training. The MCRA may be used to support a standalone study of high impact to vision injury care or the generation of clinical research data in preparation for a more expansive study. Research must align with at least one of the FY26 VRP Focus Areas. The MCRA may not be used to support preclinical research or clinical trials. Distinctive Features: Key personnel must include an established clinician or Ph.D. clinical scientist, who will serve as Principal Investigator (PI) and a clinician in training (e.g., a fellow, resident, junior clinician, clinician in a Ph.D. program), who will conduct the proposed research under mentorship of the PI, with support from supporting personnel as appropriate. The clinician in training should have sufficient time remaining in their training program to complete the research proposed under the MCRA. Scored peer review criteria include Research Idea/Rationale, Research Strategy and Feasibility, Impact and Personnel. Programmatic review criteria include adherence to the intent of the MCRA, contribution to program portfolio, relative impact and relevance to military health. Applicants must submit documentation of Institutional Review Board (IRB)/Ethics Committee (EC) approval or exemption by January 1, 2027, in order for the MCRA application to be considered for funding. https://cdmrp.health.mil/pubs/press/2026/vrppreann

2026-09-10